A Phase 4 interventional study of Dexamethasone and Etoposide in Hemophagocytic Lymphohistiocytoses and Cytokine Storm, sponsored by The Children's Hospital of Zhejiang University School of Medicine. Recruiting at 1 site in China. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2022-10-06.
Sponsored by The Children's Hospital of Zhejiang University School of Medicine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic — 3 open to participants now, 3 under way, 1 of them phase 3. Etoposide · Lymphohistiocytosis, Hemophagocytic.
Among the 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic, this one has the largest planned enrollment, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 11th registered.
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
Browse Lymphohistiocytosis, Hemophagocytic studies →3 of the 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic are open now, in 2 countries. Recruiting first, the newest first:
Beijing Friendship Hospital · Sites in China
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Etoposide: first FDA approval 1983 (VEPESID). What it is approved for, and how studies give it, is on its page →
Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 1 Day to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.
Median enrollment 31 across the 13 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
The Children's Hospital of Zhejiang University School of Medicine is the lead sponsor of 69 studies on the registry; 52 are open to participants now.
The Children's Hospital of Zhejiang University School of Medicine has 1 study filed under Lymphohistiocytosis, Hemophagocytic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children. Stratification strategy and individualized treatment is important to improve the survival. In our recent retrospective study, risk stratification based on IL-10 and IFN-γ levels well distinguished patients with different outcomes. In this multicenter prospective study, we will enroll the newly diagnosed pediatric HLH patients and divide them into low, intermediate and high-risk cytokine groups according to IFN-γ and IL-10 levels. The patients'clinical manifestation and laboratory findings will be further evaluated into severe and non-severe groups. For low/intermediate risk and non-severe patients, steroid or ruxolitinib will be used initially; while those with high risk or severe diseases, DXM+VP16±ruxolitinib will be administered. The treatment strategy could be adjusted after evaluation 48-72 hours later.
Background and objectives: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children. Early death is an important issue in HLH treatment, which is greatly caused by hypercytokinemia resulting in multi-organ disfunction and partially due to the treatment toxicities. Thus, stratification strategy and individualized treatment is important to improve the survival. In our recent retrospective study which enrolled 256 pediatric patients, the patients were stratified into low, intermediate and high risk according to their IL-10 and IFN-γ levels. The 8-week mortality for low, intermediate and high-risk patients were 5.4±2.4%, 16.9±3.4% and 48.7±8.0%, and the 5-year OS rate were 82.9±40%, 67.0±4.3% and 51.3±8.0%, respectively. This indicated that IFN-γ and IL-10 are helpful for stratifying HLH patients into different risk groups to receive individualized therapies. However, evidence of cytokine application based on multi-center prospective study is still lacking. The aim of this protocol is to establish a model to early identify the patients with low and high mortality and to guide the precise treatment of pediatric HLH.
Methods and protocol design: A multicenter prospective study in Asian countries is to be launched for children with HLH. The inclusion criterion is newly diagnosed pediatric HLH patients who has not received steroids or etoposide when enrollment. In this study, the patients are identified as low, intermediate and high-risk cytokine groups according to their cytokine levels: (1) low-risk: IFN-γ\<3700pg/mL and IL-10\<200pg/mL; (2) intermediate-risk: IFN-γ\<3700pg/mL and IL-10≥200pg/mL; (3) high-risk: IFN-γ≥3700pg/mL. The patients' clinical manifestation and laboratory findings were evaluated as well and those fulfill either one of the following criteria were considered as "severe": (1) present ≥2 out of 3 ⅰ, albumin\<26.0 g/L; ⅱ, direct bilirubin>55.0μmol/L; ⅲ, fibrinogen\<0.75g/L. (2) CNS involvement, shock, mechanical ventilation, renal failure.
Based on the cytokine risk and disease severity, different intensity of treatment will be started. For low/intermediate risk and not severe patients, steroid or ruxolitinib will be used initially; while those with high risk or "severe" disease, DXM+VP16±ruxolitinib will be administered. The treatment strategy could be adjusted after evaluation 48-72 hours later based on treatment respose and cytokine levels. A total of 400 pediatric patients under 18 years old are to be recruited. The primary end-point of the study is the 8-week responsive rates and mortality, and one-year overall survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexamethasone (DXM): week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.
Drug: Dexamethasone
Ruxolitinib(Ruxo): body weight (BW)\<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; \>20kg: 10mg Bid; Orally for 4 weeks.
Drug: Ruxolitinib
DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering. Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8.
Drug: Dexamethasone · Drug: Etoposide
DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering. Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8. Ruxolitinib(Ruxo): body weight (BW)\<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; \>20kg: 10mg Bid; Orally for 4 weeks.
Drug: Dexamethasone · Drug: Etoposide · Drug: Ruxolitinib
Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
Also known as: Steroid, Corticosteroid
Used in severe group combined with etoposide.
Also known as: VP16
Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
Also known as: JAK1/2 inhibitor
Complete remission (CR)
Complete remission rate in 8th week
Time frame: 8th week after the initial of therapy
Overall survival (OS)
Overall survival rate in one year
Time frame: One year after enrollment
overall response rate (ORR)
including the proportion of patients achieving CR, PR and HLH improvement
Time frame: At the 4th and 8th week of treatment
Mortality
8-week mortality
Time frame: At the 8th week of diagnosis
Reactivation rate
The relapse rate of disease
Time frame: Any time during the first year after diagnosis
Partial remission (PR)
Partial remission rate in 4th week
Time frame: 4th week after the initial of therapy
Rate of Early Death
Death occurred within 2 weeks after diagnosis
Time frame: 2nd week after diagnosis
Plan to share: No
Started Sep 2022 (actual). Primary completion is estimated for Dec 2024, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Etoposide · Ruxolitinib
Lymphohistiocytosis, Hemophagocytic →
The Children's Hospital of Zhejiang University School of Medicine